E-cadherin expression in prostate adenocarcinomas in Chinese and its pathological correlates

Urologia Internationalis

Volumn 73, Issue 1, 2004, Pages 36-40

  Hsu, Yen Shen ^a,c   Wang, Jyh Seng ^b,c   Wu, Tony T ^b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cadherin; Prostate neoplasm; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CAUCASIAN; CHINESE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FREQUENCY ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STAINING;

ADENOCARCINOMA; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CADHERINS; CHINA; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 3242772276     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078802     Document Type: Article

References (29)

1. Cancer Registration System, Department of Health, Taiwan, ROC; available from URL: http://crs.cph.ntu.edu.tw [accessed July 16, 2003].
2. Quinn M, Babb P: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. I. International comparisons. BJU Int 2002;90:162-173.
3. Wu TT, Huang JK: Annual changes in the clinical features of prostatic adenocarcinoma in Taiwan. BJU Int 2001;87:57-60.
4. Zhau HE, Zhao LS, Chung LWK, Chen B-Q, Troncoso P, Kao C, Kojima M, Symmans WF, Zheng N, Palmer JL, Moul JW, Davis R, Ye MF, Xiao LS, Hall MC: Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: Characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urol Oncol 1995;1:51-63.
5. Stanford JL, Damber JE, Fair WR, Sancho-Garnier H, Griffiths K, Gu F-L, Kiemeney LA: Epidemiology of prostate cancer; in Murphy G, Khoury S, Partin A, Denis L (eds): Prostate Cancer, Proceedings 2nd International Consultation on Prostate Cancer. Plymouth, Plymbridge Distributors, 1999, pp 23-57.
6. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M: E-cadherin mediated adhesion system in cancer cells. Cancer 1996;77:1605-1613.
7. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, Debruyne FMJ, Isaacs WB: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:2104-2109.
8. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
9. Richmond PJM, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M: Aberrant E-cadherin and a-catenin expression in prostate cancer: Correlation with patient survival. Cancer Res 1997;57:3189-3193.
10. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI: E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999;53:707-713.
11. Gleason DF: Veterans Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostatic carcinoma; in Tannenbaum M (ed): Urological Pathology: The Prostate. Philadelphia, Lea & Febiger, 1977, pp 171-197.
12. Sobin LH, Wittekind C (eds): TNM Classi. cation of Malignant Tumors, ed 5. New York, Wiley-Liss, 1997, p 170.
13. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748.
14. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W: E-cadherin expression in squamous cell carcinomas of head and neck: Inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991;51:6328-6337.
15. Takeichi M: The cadherins: Cell-cell adhesion molecules controlling animal morphogenesis. Development 1988;102:639-655.
16. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-1455.
17. Hinck L, Nähke IS, Papkoff J, Nelson WJ: Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly. J Cell Biol 1994;125:1327-1340.
18. Edelman GM: Cell adhesion molecules in the regulation of animal form and tissue pattern. Ann Rev Cell Biol 1986;2:81-116.
19. Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, Funke I: E-cadherin expression in primary and metastatic gastric cancer: Down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993;53:1690-1695.
20. Syrigos KN, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, Verne J, Epenetos AA, Pignatelli M: E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: Correlation with histopathological grade, tumor stage and survival. Int J Cancer 1995;64:367-370.
21. Kadowaki T, Shiozaki H, Inoue M, Tamura S, Oka H, Doki H, Iihara K, Matsui S, Iwazawa T, Nagafuchi A, Tsukita S, Mori T: E-cadherin and α-catenin expression in human esophageal cancer. Cancer Res 1994;54:291-296.
22. Rimm DL, Sinard JH, Morrow JS: Reduced α-catenin and E-cadherin expression in breast cancer. Lab Invest 1995;72:506-512.
23. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990;87:8751-8755.
24. Mansouri A, Spurr N, Goodfellow PN, Kemler R: Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin. Differentiation 1988;38:67-71.
25. Ruijterc E, van de Kaa C, Adaders T, Ruiter D, Miller G, Debruyne F, members of the BIOMED-II markers for prostate cancer study group, Schalken J: Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. Mod Pathol 1998;11:276-281.
26. Loric S, Paradis V, Gala JL, Berteau P, Bedossa P, Benoit G, Eschwege P: Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer 2001;37:1475-1481.
27. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA: Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999;161:1238-1243.
28. Giroldi LA, Bringuier PP, Schalken JA: Defective E-cadherin function in urological cancers: Clinical implications and molecular mechanisms. Invasion Metastasis 1994;14:71-81.
29. Wu TT, Hsu YS, Wang JS, Lee YH, Huang JK: The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol 2003;170:78-81.